Journal issues > Issue 1, February 2023 > Highlights in acute myeloid leukaemia

Highlights in acute myeloid leukaemia

By: J. Blokken PhD, PharmD, T. Feys MBA, MSc

SUMMARY

During the 64^th annual meeting of ASH, again hundreds of interesting oral abstracts and poster presentations in the field of acute myeloid leukaemia were discussed. In this article, we will highlight some of the most promising data in the field of novel therapeutic agents, with interesting studies on gilteritinib and quizartinib. Furthermore, several trials assessed new induction strategies and reported on biomarker and/or minimal residual disease investigations. Finally, we discuss some practice-changing data from the ASAP and VIALE-A trials.

(BELG J HEMATOL 2023;14(1):30–5)

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top